

Review Clin Transl Oncol. 2025 Feb 1. doi: 10.1007/s12094-025-03849-6. Online ahead of print.

# Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma

Siddharth Shah <sup>1</sup>, Aiswarya Nag <sup>2</sup>, Brandon Lucke-Wold <sup>2</sup>

Affiliations

PMID: 39893330 DOI: [10.1007/s12094-025-03849-6](https://doi.org/10.1007/s12094-025-03849-6)

## Abstract

Glioblastoma (GBM) is a rare and aggressive primary central nervous system tumor with high morbidity and mortality. Standard treatments include surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy, but these options are often insufficient and cause severe side effects. Tumor Treating Fields (TTFields) have emerged as a fourth treatment, offering improved survival, better prognosis, and minimal side effects, significantly enhancing the quality of life for GBM patients. For newly diagnosed cases, TTFields combined with TMZ is the recommended standard of care for eligible patients. Current GBM therapy focuses on extending survival while reducing harm. Ongoing research seeks to explore TTFields in innovative radiological-based therapeutic paradigms.

**Keywords:** Brain tumor; Glioblastoma; Neurosurgery; Survival; TTFields.

© 2025. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

[PubMed Disclaimer](#)